Lir Life Sciences Corp. Stock
€0.88
Your prediction
Financial data and news for Lir Life Sciences Corp.
sharewise wants to provide you with the best news and tools for Lir Life Sciences Corp., so we directly link to the best financial data sources.
Financials
News
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Vancouver, Canada – February 5, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Vancouver, Canada – January 29, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce positive interim
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
Vancouver, Canada – January 22, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the completion of a study design for
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
Vancouver, Canada – January 15, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the launch of a
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
Vancouver, Canada – January 8, 2026 – LIR Life Sciences Corp. (CSE: SKNY) (OTCPK: BBCMF) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Vancouver, Canada – December 18, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 11, 2025 – LIR Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies
Vancouver, Canada – December 10, 2025 – Lir Life Sciences Corp. (CSE: SKNY) (Frankfurt: N790, WKN: A41QA9) ("Lir" or the "Company") is pleased to announce the design of a new comparative